BioGaia

In one line: The best moat found anywhere in the search, at 23× EBIT and a 2.3% free cash flow yield, with the balance-sheet fortress spent and the dividend cut 42%.

Nothing here is a criticism of the business. Gross margin has been flat between 72.6% and 73.4% for four years, which is what zero pricing pressure looks like. Capital expenditure was SEK 3.6m against SEK 1.5bn of revenue — about as capital-light as commerce gets, which is why return on capital is 66%. It holds a 68% brand-of-choice rating among European paediatricians backed by roughly 290 published clinical studies, a distribution moat a private-label rival cannot simply buy. The most recent quarter grew 12% organically with a 33% adjusted operating margin.

The problem is entirely the price, and the balance sheet behind it.

Dividends of roughly SEK 698m in each of 2024 and 2025 against net income near SEK 350m — about twice earnings, funded by draining the cash pile. Retained earnings are down to SEK 123m, and the 2026 dividend was cut 42%. A screen scoring this business on net cash was scoring a fortress that has largely been paid out.

Two further cautions. Return on equity rose from 18.0% to 25.3% between 2023 and 2025 while net income fell — the improvement is purely the shrinking denominator, so any ROE-driven screen reads this backwards. And cash conversion has weakened: free cash flow to EBIT has gone 0.66 → 0.71 → 0.56.

Meanwhile the shares have re-rated up, from 18.6× to 24.0× operating profit since 2022, which is the opposite of every other candidate examined. Sitting near its 200-week average means something quite different here: the average rose to meet a share price that has gone sideways for four years, rather than the price falling to the average.

A great business at a full price is not a buy. It is a watch-list entry with a number attached.